Skip to main content

Peer Review reports

From: Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial

Original Submission
22 May 2024 Submitted Original manuscript
31 May 2024 Author responded Author comments - Haihua Yang
Resubmission - Version 2
31 May 2024 Submitted Manuscript version 2
12 Jul 2024 Reviewed Reviewer Report - Burak Bilgin
14 Jul 2024 Reviewed Reviewer Report
9 Aug 2024 Reviewed Reviewer Report
26 Aug 2024 Author responded Author comments - Haihua Yang
Resubmission - Version 3
26 Aug 2024 Submitted Manuscript version 3
9 Sep 2024 Author responded Author comments - Haihua Yang
Resubmission - Version 4
9 Sep 2024 Submitted Manuscript version 4
Publishing
13 Sep 2024 Editorially accepted
27 Sep 2024 Article published 10.1186/s12885-024-12954-8

You can find further information about peer review here.

Back to article page